LLBO Stock Overview
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Lifeline Biotechnologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.004 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -33.33% |
| 3 Month Change | -33.33% |
| 1 Year Change | 0% |
| 3 Year Change | -92.86% |
| 5 Year Change | -88.24% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| LLBO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -33.3% | 1.6% | 1.0% |
| 1Y | 0% | -1.4% | 21.9% |
Return vs Industry: LLBO matched the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: LLBO underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| LLBO volatility | |
|---|---|
| LLBO Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LLBO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine LLBO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | n/a | Jim Holmes | www.lbti.co |
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women.
Lifeline Biotechnologies, Inc. Fundamentals Summary
| LLBO fundamental statistics | |
|---|---|
| Market cap | US$869.78k |
| Earnings (TTM) | -US$574.27k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs LLBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLBO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$574.27k |
| Earnings | -US$574.27k |
Last Reported Earnings
Dec 31, 2009
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did LLBO perform over the long term?
See historical performance and comparison